Regenerative Medical Technology Group Inc.
RMTGdata completeness 88%9 fiscal years on fileData notes: no data for concept 'pretaxIncome'
i. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $437,8871 | $1.53M2 | $2.41M3 | $4.11M4 | $5.1M4 |
| Net income | −$12.9M5 | −$5.51M6 | −$9.81M7 | −$5.56M8 | −$7.81M8 |
| Operating cash flow | −$9.88M9 | −$1.11M10 | −$419,19911 | $850,69912 | −$706,51912 |
| Capital expenditure | — | $198,42813 | $385,59614 | $215,41915 | $602,58315 |
| Free cash flow (derived) | — | −$1.31M10 | −$804,79511 | $635,28012 | −$1.31M12 |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $2.98M16 | $1.65M17 | $530,54017 | $1.17M18 | $956,71818 |
| Diluted shares | 11.5M | 12.2M | 12.4M | 12.5M | 12.6M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$27.5
your share of equity
Profit it earned you last year
−$6.18
Free cash flow it threw off
−$1.04
Debt you’d be carrying
—
10 shares is a claim on −$27.5 of net worth that earned you −$6.18 and generated −$1.04 of cash last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+10% shares · 5y
Share count is up 10% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2021-12-31 · accession 0001213900-23-029942 (Revenues)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (Revenues)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (Revenues)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (Revenues)
- 10-K · period ending 2021-12-31 · accession 0001213900-23-029942 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001213900-23-029942 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001213900-22-024049 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (CashAndCashEquivalentsAtCarryingValue)